BABA 385 million war investment Zhongxin tourism; a Chinese stock rose more than 1000% in intraday trading, has obtained rapid pathogen diagnosis technology; Tencent privatized Sogou reached a final agreement, Sogou, Sohu.com Ltd both closed up; Huazhu: Bonitas supplementary short selling report contains many erroneous, unsubstantiated statements.

The US stock market fell across the board on Tuesday, and the counterattack of COVID-19 's epidemic became an important factor in depressing the market, as investors focused on the first debate of the upcoming US presidential election. Hot Chinese stocks are up and down.

The specific performance is as follows:

In terms of large-scale China-listed stocksBABA is up 0.32%, Baidu, Inc. is down 2.75%, NetEase, Inc is down 2.84%, Pinduoduo is down 1.86%, Weibo Corp is down 3.75%, iQIYI, Inc. is up 0.97%, TAL Education Group is up 0.57% and New Oriental Education & Technology Group is down 1.57%.

Other hot Chinese stocksQingdao TDH Holdings Inc Foods rose 24.04%, Pintec Technology Holdings 16.69%, Ambow Education Holding Ltd 15.89%, Luokung Technology Corp 14.13%, Deswell Industries Inc 12.72%, Dunxin Financial Holdings Ltd 12.07%, contact Intelligence 12.01%, Sohu.com Ltd 11.42%, NIO Inc. 10.85%, Yiren Digital Ltd. American Depositary Shares 10.39%, Moxian Inc 10.16%.

The ones with larger declines are，SPI Greenengbao plunged 27.15%, The9 Ltd plunged 26.14% CBAK energy technology fell 10.27%.

Focus review

• NIO Inc. car rose nearly 11%, Deutsche Bank analyst: NIO Inc. is as popular as BMW and Mercedes-Benz

$NIO Inc. (NIO.US) $Auto shares closed up 10.85% at $20.85 on Tuesday, hitting an all-time high of $21.12. Deutsche Bank had previously released a report saying that NIO Inc. could become the next iconic car brand.

Edison Yu, an analyst at Deutsche Bank, said that more and more customers believe that NIO Inc. Automobile is a high-end brand with the most first-class technology and service in its kind of products. At the same time, in a recent study on the brand preference of major electric vehicles, NIO Inc. 's recommendation rate was as high as 62%. The study shows that customers' preference for NIO Inc. cars is as high as that of BMW and Mercedes-Benz. With the improvement of the popularity of pure electric vehicles and the increase of word-of-mouth, consumers will know more about NIO Inc. 's products and services. It is believed that NIO Inc. can occupy a higher share in the high-end market.

NIO Inc. 's delivery is expected to hit an all-time high in the third and fourth quarters, driven by its SUV EC6, the report said. Deutsche Bank maintains its "buy" rating on NIO Inc. and maintains its target share price of $24.

• Tencent privatized Sogou reached a final agreement! Sogou and Sohu.com Ltd both closed higher.

$Sohu.com Ltd (SOHU.US) $Tuesday closed up 11.42% at $20.10.$Sogou (SOGO.US) $It closed up 2.31% at $8.87. Sogou issued an announcement yesterday, announcing the signing of a final privatization agreement. According to the announcement, the transaction is expected to be completed in the fourth quarter of 2020. After the completion of the merger, Sogou will become an indirect wholly-owned subsidiary of Tencent, and his American depositary receipts will no longer be listed on the New York Stock Exchange. The deal, priced at $9 / ADS, is expected to close in the fourth quarter of 2020. Sohu.com Ltd search will receive a total of about $1.18 billion in cash. Sohu.com Ltd will no longer have any beneficial interest in Sogou after the transaction is completed.

• KE Holdings Inc. rose nearly 7%, and his share price hit an all-time high.

$KE Holdings Inc. (BEKE.US) $It rose in a straight line at the beginning of the session, rising more than 9% at one point, closing up 6.91% at $65.63, continuing to hit a new high since listing, with a total market capitalization of $75.04 billion. KE Holdings Inc. has risen for five consecutive trading days, a total of 25.3%.

• Huazhu: Bonitas Supplementary short selling report contains many erroneous and unsubstantiated statements

$Huazhu Group Limited (HTHT.US) $The supplementary short selling report issued by Bonitas Research on September 29 has no basis and contains many errors, unsubstantiated statements and misleading conclusions about the company's business and operations. In view of the fact that the Company has responded twice to Bonitas Research's allegations, the Company may not respond to Bonitas Research's future allegations unless required by applicable law or listing rules, and the market should not interpret this as admitting any future allegations.

• BABA invested in Zhongxin Tourism in 385 million.

On the evening of September 29th, Zhongxin Tourism announced that Feng Bin, the company's controlling shareholder and actual controller, transferred his 45.47 million unlimited terms of circulation shares of Zhongxin Tourism to the BABA network at a price of 8.46 yuan per share. it accounts for about 5% of the total share capital of Zhongxin Tourism signed by the share transfer agreement.$BABA (BABA.US) $Become the third largest shareholder of Zhongxin Tourism.

• Aptorum Group LtdRose more than 1000% in intraday trading.To obtain rapid pathogen diagnosis technology

Medium-sized stocks with small market capitalization$Aptorum Group Ltd (APM.US) $Shares rose sharply on Tuesday, triggering circuit breakers twice in the first two days of the session, rising as much as more than 1000% to close up 290.16% at $4.76. Aptorum Group Ltd issued an announcement on Tuesday announcing the establishment of a liquid biological detection subsidiary for infectious diseases, Aptorum Innovations, and jointly developing innovative molecular-based rapid pathogen identification and detection and diagnosis (RPIDD) technology through a recent exclusive license agreement with Accelerate Technologies Pte Ltd, a commercial branch of the Science and Technology Research Council of Singapore. Through its RPIDD technology, Aptorum Innovations targets the molecular diagnostics market, which is expected to reach $13.8 billion in 2025, of which 60 per cent is expected to be in the field of infectious diseases.